Brief: FDA Accepts For Priority Review Ascendis Pharma's NDA For TransCon PTH In Adult Patients With Hypoparathyroidism

Ascendis Pharma A/S

31/10/2022 12:10

Oct 31 (Reuters) - Ascendis Pharma A/S  ASND.O :
    * FDA ACCEPTS FOR PRIORITY REVIEW ASCENDIS PHARMA’S NDA FOR
TRANSCON™ PTH IN ADULT PATIENTS WITH HYPOPARATHYROIDISM
    * ASCENDIS PHARMA A/S - PDUFA TARGET ACTION DATE IS APRIL
30, 2023
    * ASCENDIS PHARMA A/S - MAA SUBMISSION TO EMA ON TRACK FOR
THIS
QUARTER

Source text for Eikon:  ID:nGNX98Gm6C 
Further company coverage:  ASND.O 
 ((Reuters.Briefs@thomsonreuters.com;;))